279 related articles for article (PubMed ID: 21385170)
1. Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms.
Ossenkoppele GJ; van de Loosdrecht AA; Schuurhuis GJ
Br J Haematol; 2011 May; 153(4):421-36. PubMed ID: 21385170
[TBL] [Abstract][Full Text] [Related]
2. Flow cytometric determination of atypical antigen expression in acute leukemia for the study of minimal residual disease.
Drach J; Drach D; Glassl H; Gattringer C; Huber H
Cytometry; 1992; 13(8):893-901. PubMed ID: 1459006
[TBL] [Abstract][Full Text] [Related]
3. [Immunophenotyping in acute leukemia: detection of minimal residual disease].
Pálóczi K; Nahajevszky S; Jakab K; Regéczy N; Gopcsa L; László E; Földi J
Orv Hetil; 2000 Nov; 141(46):2487-92. PubMed ID: 11126681
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic potential of CD34+ cell antigen expression in myelodysplastic syndromes.
De Smet D; Trullemans F; Jochmans K; Renmans W; Smet L; Heylen O; Bael AM; Schots R; Leus B; De Waele M
Am J Clin Pathol; 2012 Nov; 138(5):732-43. PubMed ID: 23086775
[TBL] [Abstract][Full Text] [Related]
5. Flow cytometric scoring system (FCMSS) assisted diagnosis of myelodysplastic syndromes (MDS) and the biological significance of FCMSS-based immunophenotypes.
Xu F; Li X; Wu L; He Q; Zhang Z; Chang C
Br J Haematol; 2010 May; 149(4):587-97. PubMed ID: 20331463
[TBL] [Abstract][Full Text] [Related]
6. Increased immature hematopoietic progenitor cells CD34+/CD38dim in myelodysplasia.
Monreal MB; Pardo ML; Pavlovsky MA; Fernandez I; Corrado CS; Giere I; Sapia S; Pavlovsky S
Cytometry B Clin Cytom; 2006 Mar; 70(2):63-70. PubMed ID: 16470534
[TBL] [Abstract][Full Text] [Related]
7. Immunophenotypic characteristics of acute leukaemia after myelodysplastic syndromes.
Lima M; Teixeira Mdos A; Morais S; Cunha M; Coutinho J; Pinho L; Ribeiro P; Justiça B
Sangre (Barc); 1995 Feb; 40(1):49-52. PubMed ID: 7716672
[TBL] [Abstract][Full Text] [Related]
8. The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells.
Grabrucker C; Liepert A; Dreyig J; Kremser A; Kroell T; Freudenreich M; Schmid C; Schweiger C; Tischer J; Kolb HJ; Schmetzer H
J Immunother; 2010 Jun; 33(5):523-37. PubMed ID: 20463595
[TBL] [Abstract][Full Text] [Related]
9. Transformation of myelodysplastic syndromes into acute myeloid leukemias.
Shi J; Shao ZH; Liu H; Bai J; Cao YR; He GS; Tu MF; Wang XL; Hao YS; Yang TY; Yang CL
Chin Med J (Engl); 2004 Jul; 117(7):963-7. PubMed ID: 15265365
[TBL] [Abstract][Full Text] [Related]
10. Immunological evaluation of minimal residual disease (MRD) in acute myeloid leukaemia (AML).
San-Miguel JF; Vidriales MB; Orfão A
Best Pract Res Clin Haematol; 2002 Mar; 15(1):105-18. PubMed ID: 11987919
[TBL] [Abstract][Full Text] [Related]
11. Leukemia-associated marker combinations in acute leukemia suitable for detection of minimal residual disease.
Babusíková O; Mesárosová A; Koníková M; Kusenda J; Glasová M; Klobusická M
Neoplasma; 1993; 40(5):275-81. PubMed ID: 8272155
[TBL] [Abstract][Full Text] [Related]
12. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
Orazi A
Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cells (DCs) can be successfully generated from leukemic blasts in individual patients with AML or MDS: an evaluation of different methods.
Kremser A; Dressig J; Grabrucker C; Liepert A; Kroell T; Scholl N; Schmid C; Tischer J; Kufner S; Salih H; Kolb HJ; Schmetzer H
J Immunother; 2010; 33(2):185-99. PubMed ID: 20139775
[TBL] [Abstract][Full Text] [Related]
14. The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia.
Al-Mawali A; Gillis D; Lewis I
Am J Clin Pathol; 2009 Jan; 131(1):16-26. PubMed ID: 19095561
[TBL] [Abstract][Full Text] [Related]
15. Clinical applications of molecular haematology: flow cytometry in leukaemias and myelodysplastic syndromes.
Dalal BI
J Assoc Physicians India; 2007 Aug; 55():571-3. PubMed ID: 18019799
[TBL] [Abstract][Full Text] [Related]
16. Immunophenotyping for diagnosis and prognosis in MDS: ready for general application?
Cremers EM; Alhan C; Westers TM; Ossenkoppele GJ; van de Loosdrecht AA
Best Pract Res Clin Haematol; 2015 Mar; 28(1):14-21. PubMed ID: 25659726
[TBL] [Abstract][Full Text] [Related]
17. Monitoring of minimal residual disease in acute myeloid leukemia.
Kern W; Haferlach C; Haferlach T; Schnittger S
Cancer; 2008 Jan; 112(1):4-16. PubMed ID: 18000811
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive flow cytometry phenotype in acute leukemia at diagnosis and at relapse.
Li X; Du W; Liu W; Li X; Li H; Huang SA
APMIS; 2010 May; 118(5):353-9. PubMed ID: 20477810
[TBL] [Abstract][Full Text] [Related]
19. Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes.
Cilloni D; Gottardi E; Messa F; Fava M; Scaravaglio P; Bertini M; Girotto M; Marinone C; Ferrero D; Gallamini A; Levis A; Saglio G;
J Clin Oncol; 2003 May; 21(10):1988-95. PubMed ID: 12743153
[TBL] [Abstract][Full Text] [Related]
20. Lack of expression of the chondroitin sulphate proteoglycan neuron-glial antigen 2 on candidate stem cell populations in paediatric acute myeloid leukaemia/abn(11q23) and acute lymphoblastic leukaemia/t(4;11).
Neudenberger J; Hotfilder M; Rosemann A; Langebrake C; Reinhardt D; Pieters R; Schrauder A; Schrappe M; Röttgers S; Harbott J; Vormoor J
Br J Haematol; 2006 May; 133(3):337-44. PubMed ID: 16643437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]